miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation
Silvia Moimas(International Centre for Genetic Engineering and Biotechnology), Marco Confalonieri(Ospedale di Cattinara)
Cited by 59
Related Papers
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
|Pharmaceuticals|2024|86
The time to offer treatments for COVID-19
|Expert Opinion on Investigational Drugs|2021|32
The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
|Pharmaceuticals|2025|6
Comorbidities’ Effect on IPF: Pathogenesis and Management
|Biomedicines|2025|3